Travus Therapeutics Financing
Travus Therapeutics, Inc., Corporation just had published form D announcing $2.25 million debt financing. This is a new filing. Travus Therapeutics was able to sell $750,000 so far. That is 33.33% of the fundraising offer. The total fundraising amount was $2.25 million. This form was filed on 2016-07-08. The reason for the financing was: Securities offered consist of promissory notes convertible into shares of convertible preferred stock, warrants exercisable for shares of convertible preferred stock and the common stock underlying the convertible preferred stock.. The fundraising still has about $1.50 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Travus Therapeutics is based in North Carolina. The filler’s business is Biotechnology. The D form was signed by John Finn President. The company was incorporated in 2014. The filler’s address is: 101 N. Chestnut St., Suite 104, Winston-Salem, Nc, North Carolina, 27101. John Finn is the related person in the form and it has address: 101 N. Chestnut St., Suite 104, Winston-Salem, Nc, North Carolina, 27101. Link to Travus Therapeutics Filing: 000167800716000001.
Analysis of Travus Therapeutics Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering size. Travus Therapeutics sold 33.33% of the offering. The financing is still open. The average investment offering size for companies in the Biotechnology industry is $3.08 million. The offering was 75.65% smaller than the average of $3.08 million. Of course this should not be taken as negative. Startups get financed for a variety of needs and reasons. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Travus Therapeutics Also
The Form D signed by John Finn might help Travus Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.